


# OPTIMISATION DU CONTRÔLE THERMIQUE APRES ARRET CARDIAQUE: des ACSOS au CCT

Nicolas DEYE The Chain of Survival  
Medical ICU  
Inserm U-942  
Lariboisière University Hospital, Paris  
nicolas.deye@aphp.fr



The Chain of Survival diagram is a horizontal chain of four interconnected circles. The first circle is labeled 'Early CPR' and contains an icon of a person being resuscitated. The second circle is labeled 'Early Defibrillation' and contains a lightning bolt icon. The third circle is labeled 'Early ACLS' and contains an icon of a person receiving medical treatment. The fourth circle is labeled 'Early Post-Resuscitation Care' and contains a thermometer and a heart icon. The text 'The Chain of Survival' is written in red above the diagram.

# Cardiac arrest

No Flow

Low Flow

ROSC

**Primary brain injury**  
(excito-toxicity, free radicals release, inflammation, necrosis, apoptosis)

Reperfusion damages ("SIRS")

- At tissular level

- At cellular level

(oedema, rise in ICP, herniation, loss of vasoreactivity, vasoconstriction, reperfusion insult, free radicals release, inflammation, excito-toxicity)

**Systemic induced secondary cerebral insults (ACSOS)**

Hypo/hyperoxia, hypo/hyperglycemia


Hypo/hyperercapnia, acidosis

Hypo/hypertension

**Hyperthermia +++**


**Secondary brain injury**  
(necrosis, apoptosis)

**Definitive brain injury**



# OPTIMIZING TTM/TH PROTOCOL

## OPTIMAL LEVEL OF TEMPERATURE



# Normal temperature? Abnormal damages

Holtzclaw. Sessler. 2000  $37,0 \pm 0,6^{\circ}\text{C}$

Villers. 2003  $36,6 \pm 0,4^{\circ}\text{C}$


Central compartments "core" (trunk, head)  $\approx 2$  to  $4^{\circ}\text{C}$   
above periph. (surface: skin)

Precise thermoregulation (hypothalamus: intact or not)


Variations (day, month...)

« Cerebral  
thermo-pooling »

normal core body temperature of a  
healthy, adult human being




Harris, 2008



# Hyperthermia After Cardiac Arrest Is Associated With an Unfavorable Neurologic Outcome

Andrea Zeiner, MD; Michael Holzer, MD; Fritz Sterz, MD; Waltraud Schörkhuber, MD; Philip Eisenburger, MD; Christof Havel, MD; Andreas Kliegel, MD; Anton N. Laggner, MD

Arch Intern Med 2001



Body Temperature*	Functional Neurologic Recovery†		P
	Good (n = 89)	Unfavorable (n = 62)	
On admission to the emergency department	35.6 (34.2-36.0)	35.3 (34.0-35.9)	.39
Minimum	36.0 (35.2-36.2)	35.2 (34.7-35.7)	.001
Maximum	37.7 (36.9-38.6)	38.3 (37.8-38.9)	<.001
$\Delta(+37)$	0.25 (0.00-0.78)	0.66 (0.17-1.00)	.002

Variable	OR (95% CI)	p
No flow	1.34 (1.16-1.55)	<0.001
Low flow	1.05 (1.01-1.09)	.01
Maximal temp	2.26 (1.24-4.12)	.008

**Survivors are less hypothermic on admission but less febrile thereafter**

Part 8: Advanced Life Support: 2010 International Consensus on  
Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science  
With Treatment Recommendations

Laurie J. Morrison, Charles D. Deakin, Peter T. Morley, Clifton W. Callaway, Richard E. Kerber, Steven L. Kronick, Eric J. Lavonas, Mark S. Link, Robert W. Neumar, Charles W. Otto, Michael Parr, Michael Shuster, Kjetil Sunde, Mary Ann Peberdy, Wanchun Tang, Terry L. Vanden Hoek, Bernd W. Böttiger, Saul Drajer, Swee Han Lim, Jerry P. Nolan and Advanced Life Support Chapter Collaborators  
*Circulation* 2010;122;S345-S421

**Circulation**

JOURNAL OF THE AMERICAN HEART ASSOCIATION

American Heart  
Association  
Learn and Live

From 2003-2010

## Treatment Recommendations Related to Post-Cardiac Hypothermia


- Patient who develop hyperthermia after CA have worse prognosis. Despite lack of evidence, it is reasonable to treat hyperthermia.
- Comatose adult patients (not responding in a meaningful way to verbal commands) with spontaneous circulation after out-of-hospital VF CA should be cooled to 32 to 34°C for 12 to 24 hours.
- Induced hypothermia might also benefit comatose adult patients with spontaneous circulation after OHCA from an initial non-shockable rhythm, or IHCA (low level of evidence)

NNT using TH to save 1 patient = 6 (IC<sub>95%</sub> [4-21])

When considering HACA, Australian (Bernard) and Hachimi-Idrissi trials

# Targeted Temperature Management in Critical Care

A Report and Recommendations from Five Professional Societies



11th  
International  
Consensus  
Conference

Therapeutic Hypothermia –  
To Cool or Not To Cool?



Condado Plaza Hotel and Casino  
San Juan, Puerto Rico  
April 23-24, 2009

TTM vs noTTM in HIE (neonates): weak recommendation (32.5-35.5°C, 72<sup>H</sup>)  
TTM vs noTTM in CA (VF): strong recommendation (32-34°C, 24<sup>H</sup>)



# Control = normothermia or hyperthermia?

## Limit of the 2 main RCTs in 2002

Patients in the control group slightly hyperthermic  
(37-38°C during the first 48 hours)



**No TTM**




Controversial metanalysis (NNT/NNH): Nielsen IJC 2010



Nielsen et al, 2013  
NS superiority large RCT  
(469 vs 464 pts)

ORIGINAL ARTICLE

## Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest




36°

33°

Nielsen Niklas  
NEJM 2013

ORIGINAL ARTICLE

## Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest



Variable	33°C Group	36°C Group
<b>CPC at follow-up† D180</b>		
Total no. of patients	469	464
Category — no. (%)		
1	195 (42)	183 (39)
2	23 (5)	39 (8)
3	17 (4)	20 (4)
4	6 (1)	2 (0.5)
5	228 (49)	220 (47)
P value for trend	0.85	


### No. at Risk

33°C group	473	230	151	64	15
36°C group	466	235	144	68	12

Summary of the 2 possibilities (slight TTM or HACA-TH)



# Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest




Nielsen N et al. NEJM 2013  
HACA Study. NEJM 2002

# In-hospital low TTM effect vs slight TTM or vs no TTM ?

Vargas M.  
Resu 2015


Mortality at hospital discharge

Studies	Estimate (95% C.I.)	Control	Hypothermia
Hachimi 2001	1.143 (0.867, 1.507)	13/14	13/16
Bernard 2002	1.322 (0.910, 1.920)	23/34	22/43
Holzer 2002	1.370 (1.039, 1.807)	69/138	50/137
Laurent 2005	1.008 (0.582, 1.748)	11/20	12/22
Nilesen 2013	0.991 (0.857, 1.145)	203/466	208/473
<b>Overall (I<sup>2</sup>=27%, P=0.239)</b>	<b>1.127 (0.976, 1.302)</b>	<b>319/672</b>	<b>305/691</b>
Tau <sup>2</sup> =0.007, Q (df=4)=5.507, p=0.104			




Good neurologic performance at hospital discharge

Studies	Estimate (95% C.I.)	Control	Hypothermia
Hachimi 2001	0.227 (0.012, 4.356)	0/14	2/16
Bernard 2002	0.542 (0.286, 1.026)	9/34	21/43
Holzer 2002	0.715 (0.553, 0.924)	54/137	75/136
Nielsen 2012	1.042 (0.903, 1.201)	212/465	207/473
<b>Overall (I<sup>2</sup>=70%, P=0.018)</b>	<b>0.788 (0.556, 1.116)</b>	<b>275/650</b>	<b>305/668</b>
Tau <sup>2</sup> =0.068, Q (df=3)=10.091, p=0.180			



Poor neurologic performance at hospital discharge

Studies	Estimate (95% C.I.)	Control	Hypothermia
Hachimi 2001	1.143 (0.079, 16.625)	1/14	1/16
Bernard 2002	6.286 (0.312, 126.725)	2/34	0/43
Holzer 2002	1.416 (1.130, 1.774)	87/137	61/136
Nielsen 2013	0.877 (0.614, 1.252)	50/465	58/473
<b>Overall (I<sup>2</sup>=51%, P=0.107)</b>	<b>1.179 (0.783, 1.776)</b>	<b>140/650</b>	<b>120/668</b>
Tau <sup>2</sup> =0.068 Q (df=3)=10.091, p=0.180			



**IH low TTM improved short and long term mortality compared with no TTM  
Conversely low TTM outcome did not improve compared with slight TTM**

More than 15 metaanalyses: Cochrane, CCM, CMEJ, Resu, ACA, AMJ, CC, IC...  
Remind Laurent RCT: JACC 2005 (No TTM vs HF±TH ~ 32-36° )  
Remind Lopez-De-Sa RCT: Circulation 2012 (32 vs 34° )

Jerry P. Nolan<sup>a,b,\*</sup>, Jasmeet Soar<sup>c</sup>, Alain Cariou<sup>d</sup>, Tobias Cronberg<sup>e</sup>,  
Véronique R.M. Moulaert<sup>f</sup>, Charles D. Deakin<sup>g</sup>, Bernd W. Bottiger<sup>h</sup>, Hans Friberg<sup>i</sup>,  
Kjetil Sunde<sup>j</sup>, Claudio Sandroni<sup>k</sup>

Optimising recovery

**ICU management**

- Temperature control: constant temperature 32°C – 36°C for ≥ 24h; prevent fever for at least 72 h
- Maintain normoxia and normocapnia; protective ventilation
- Optimise haemodynamics (MAP, lactate, ScvO<sub>2</sub>, CO/CI, urine output)
- Echocardiography
- Maintain normoglycaemia
- Diagnose/treat seizures (EEG, sedation, anticonvulsants)
- Delay prognostication for at least 72 h

2015  
summary  
of changes  
since 2010  
guidelines

- Maintain a constant, target temperature between 32 °C and 36 °C for those patients in whom temperature control is used (strong recommendation, moderate-quality evidence).
- Targeted temperature management remains important but there is now an option to target a temperature of 36 °C instead of the previously recommended 32–34 °C.
- Whether certain subpopulations of cardiac arrest patients may benefit from lower (32–34 °C) or higher (36 °C) temperatures remains unknown, and further research may help elucidate this.

# LESSONS FROM TTM TRIAL

Deye et al,  
AIC,2016

You can choose to treat at 36°C (1/3 of respondents) or keep 33°C


**We do not abandon TTM based on the TTM-trial**  
**One size does not fit all ! Adaptative approach?**

Storm et al.  
Resu.2017

Changing target temperature from 33 °C to 36 °C in the ICU management of out-of-hospital cardiac arrest:

A before and after study☆

Bray et al. Resuscitation 2017



After the change from TTM of 33 to 36° C, we report a low compliance with TT, higher fever rates and trends toward clinical worsening.


**STRICT PROTOCOL!**

Hospitals adopting a 36° C TT need to be aware that this should not be easy to achieve, requiring adequate sedation + NMB to avoid fever.

# OPTIMIZING TTM/TH PROTOCOL CA PATIENT'S SELECTION

	Target		Achieved	
HACA 2002 N=275	32-34	Normal	33	37.8
Bernard 2002 N=77	33	37	33	37.4
Nielsen 2013 N=939	33	36	33	36

## Conclusions from the post-arrest trials: control arm




***Control differs:  
uncontrolled  
vs. controlled***

*Modified from  
Abella BS,  
AHA Dallas 2013*



# Conclusions from the post-arrest trials



***Shockable rhythms (>95% HACA and Bernard 80% TTM)***

***Still the control arm!***


***And the rhythm (etiology?)***

Modified from  
Abella BS,  
AHA Dallas 2013

# Hypothermia & shockable rhythm



■ Hypothermie+    □ Hypothermie-



Adapted from Behringer et al.

And Polderman K, Lancet 2008



# Meta-analysis non-VF




Clinical paper

Does therapeutic hypothermia benefit adult cardiac arrest patients presenting with non-shockable initial rhythms?: A systematic review and meta-analysis of randomized and non-randomized studies<sup>☆</sup>

Young-Min Kim<sup>a</sup>, Hyeon-Woo Yim<sup>b,c</sup>, Seung-Hee Jeong<sup>c</sup>, Mary Lou Klem<sup>d</sup>, Clifton W. Callaway<sup>e,\*</sup>

Resuscitation 2012



## Neurological outcome




Fig. 4. The effect of therapeutic hypothermia on neurological outcome in non-randomized studies.


TH is associated with reduced in-hospital mortality for adults resuscitated from non-shockable CA

However, most of the studies had substantial risks of bias and quality of evidence was very low.

# Hypothermia & non-shockable rhythm



■ Hypothermie+    □ Hypothermie-



Meta-analyses: BioMedResIntern 16 (Song+, nonRCT), Crit Care 15 (Zhang-)...

# Therapeutic hypothermia after out-of-hospital cardiac arrest in Finnish intensive care units: the FINNRESUSCI study

ICM 2013. Vaahersalo J, et al.

281 shockable CA (TH 86%)

**223 non-shockable CA with TH = 70 (31%):** prolonged time to ROSC, more cardiac etiology, more pneumonia, mechanical ventilation and length of stay

64% survivors at ICU discharge (with or without TH)


At hospital discharge, 37% if TH vs 32% without TH

TH-treated 1y survival: 27%

Not-TH 1y survival: 19%


**NS**

**Non significant (p=0.56)  
even after adjustment for propensity score**



# Comparative Effectiveness of Therapeutic Hypothermia After Out-of-Hospital Cardiac Arrest: Insight from a Large Data Registry

Mader TJ, Nathanson BH, Soares WE, Coute RA, McNally BF.



## Ther Hypothermia Temp Manag. 2014

Retrospective study of OHCA adults in the CARES registry

6369 pts: shockable= 2992 (47%) ; nonshockable= 3377 (53%).

Unadjusted neurological status at hospital discharge with and without TH were similar

( $p=0.3$ ). After multivariate adjustments, **TH had no association with good neurological status at hospital discharge or TH was actually associated with worse neurological outcome, particularly in nonshockable patients**

**NS ? Harmful !?**

## Association Between Therapeutic Hypothermia and Survival After In-Hospital Cardiac Arrest

**JAMA 2016**

Paul S. Chan, MD; Robert A. Berg, MD; Yuanyuan Tang, PhD; Lesley H. Curtis, PhD; John A. Spertus, MD, MPH;  
for the American Heart Association's Get With the Guidelines-Resuscitation Investigators

26183 CA (1524 TH treated vs 3714 not treated after propensity score),

**TH was associated with lower IH survival for non shockable and for shockable rhythm, and lower rate of favorable neurological survival for the global cohort (both rhythm)**



- TTM is recommended for adults after OHCA with an initial shockable rhythm who remain unresponsive after ROSC (strong recommendation, low-quality evidence).
- TTM is suggested for adults after OHCA with an initial non-shockable rhythm who remain unresponsive after ROSC (weak recommendation, very low-quality evidence).
- TTM is suggested for adults after IHCA with any initial rhythm who remain unresponsive after ROSC (weak recommendation, very low-quality evidence).



# To cool or not to cool non-shockable cardiac arrest patients: it is time for randomized controlled trials

ICM 2013

Hétérogénéité des non choquables?!

Table 1 Pros and cons of TH in patients with non-shockable OHCA

Reason	TH strategy (target 32–34 °C)	Normothermia strategy
Pathophysiological arguments: protective effects in asphyxic animal CA models (in terms of histological and neurobehavioural scores, and survival)	+	–
Beneficial effects on survival and neurological function obtained in neonatal hypoxic-ischaemic encephalopathy (mimicking asphyxia)	+	–
Available RCTs <sup>a</sup>	?	?
Available meta-analyses <sup>a</sup>	?	–
Available non-randomized studies (registries, observational, matched studies...) <sup>a</sup>	+	?
Impact of different targeted temperature management (35–36 °C...) <sup>a</sup>	?	?
No other available treatment to date <sup>a</sup>	+	?
Could prevent neurological damage (increase in likelihood of favourable outcome, CPC 1-2) <sup>a</sup>	+	–
Could save life (decrease in likelihood of unfavourable outcome, CPC 5) <sup>a</sup>	+	?
Severity of the underlying disease (poor prognosis altering the possible impact of the treatment) <sup>a</sup>	+	?





# Fever (not hyperthermia) is not always associated with poor prognosis

## Control of fever is not always correlated with better prognosis in ICU

	ICU Population	Fever definition	Main findings on fever
<b>Circiumaru</b>	General, n=100	Fever $\geq 38.4^{\circ}\text{C}$	No impact
<b>Barie</b>	Postoperative, n=2419	Fever $\geq 38.2^{\circ}\text{C}$	No impact
<b>Laupland</b>	General, n=10,962	Normal $36^{\circ}\text{C}-38.2^{\circ}\text{C}$ Low fever $\geq 38.3^{\circ}\text{C}$ High fever $\geq 39.5^{\circ}\text{C}$	No impact
<b>Kiekkas</b>	General, n=239	Fever $\geq 38.3^{\circ}\text{C}$	Maximal body temperature associated with higher mortality
<b>Selladurai</b>	Sepsis, n=106	Fever $>38^{\circ}\text{C}$	Fever associated with higher mortality
<b>Egi</b>	Sepsis, n=606  No sepsis, n=819	Normal $36.5-37.4^{\circ}\text{C}$ Fever ranges $+1^{\circ}\text{C}$	Body temperature $37.5-38.4^{\circ}\text{C}$ associated with lower mortality  Body temperature $\geq 39.5^{\circ}\text{C}$ associated with higher mortality
<b>Netzer</b>	ALI, n=450	Fever $\geq 38^{\circ}\text{C}$ High Fever $>39^{\circ}\text{C}$	Fever associated with prolonged mechanical ventilation

Role of inflammatory response, defense against virus-bacteria... and thermomodulation (hypothalamic set-point modification for microbiological control)

Better heat shock response? Role of heat/cold shock proteins?



Fever and Antipyretic in Critically ill patients Evaluation (FACE) Study Group

Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study

In septic patients (temp. > than non-septic), fever = not associated with mortality (antipyretics independently associated with mortality)


In non-septic patients, fever >39.5° C = independently associated with death (no association between antipyretics and mortality)

Maximum body temperature during ICU stay



# Therapeutic Hypothermia after In-Hospital Cardiac Arrest in Children


Alive with VABS-II score $\geq 70$ at 1 yr	48/133 (36)	48/124 (39)	-2.6 (-14.5 to 9.2)	0.92 (0.67 to 1.27)	0.63†
Alive at 1 yr	81/166 (49)	74/161 (46)	2.8 (-8.0 to 13.7)	1.07 (0.85 to 1.34)	0.56†



All-cause mortality at 28 days — no. (%)	59 (37)	66 (41)	0.40
--	---------	---------	------

# Therapeutic Hypothermia after Out-of-Hospital Cardiac Arrest in Children

Alive with VABS-II score $\geq 70$ at 1 yr	27/138 (20)	15/122 (12)	7.3 (-1.5 to 16.1)	1.54 (0.86 to 2.76)	0.14†
Alive at 1 yr	57/151 (38)	39/136 (29)	9.1 (-1.8 to 19.9)	1.29 (0.93 to 1.79)	0.13†



**N=155 vs 140**  
**(33° vs 36.8°)**  
**P=0.04**


All-cause mortality 28 days — no./total no. (%)	87/153 (57)	93/139 (67)	0.08
---	-------------	-------------	------

# Cooling for newborns with hypoxic ischaemic encephalopathy (Review)

2013

Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG

11 RCTs included / 1505 neonates at term or end of pre-term  
with moderate to severe encephalopathy and per-partum asphyxia



- ↓ death or major neurological sequellae at 18 months  
RR 0.75 [IC 95% 0.68-0.83], NNT 7 [95%CI 5-10], 8 studies (1344 children)
- ↓ death RR 0.75 [95%CI 0.64-0.88], NNT 11 [95%CI 6-50], 11 studies
- ↓ neurological sequellae in survivors  
RR 0.77 [95%CI 0.63-0.94], NNT 8 [95%CI 5-14], 8 studies (917 children)

TH in neonates with hypoxic ischaemic encephalopathy: concordant RCTs

Neurological impairment: seizures, clinical or EEG encephalopathy, low Apgar score, acidosis, O<sub>2</sub> desaturation (perinatal asphyxia), bradycardia and/or CPR

Pilot study 05  
Pedia Neurol

Cool Cap 05

NICHD trial  
(Toby, NEJM 05)

Toby NEJM, 2009

Zhou 2010; nEURO study 2010  
Azzopardi NEJM, ICE study 2012

Concordant meta-analyses (Edwards 06-10, Jacobs CD 07-09, Shah 07, Schulzke 07), etc



# Induced hypothermia after cardiac arrest improves cardiogenic shock\*

CCM 2012



Shock

## Mild therapeutic hypothermia in cardiogenic shock syndrome\*

Carsten Zobel, MD; Christoph Adler, MS; Anna Kranz, MS; Catherine Seck, MD; Roman Pfister, MD; Martin Hellmich, MD; Matthias Kochanek, MD; Hannes Reuter, MD


Matched patients with (n=20, LVEF 42%) or without TH

Sparing in catecholamines (SVR ↑, CO preserved if fluids)



# Hemodynamics and Vasopressor Support During Targeted Temperature Management at 33°C Versus 36°C After Out-of-Hospital Cardiac Arrest: A Post Hoc Study of the Target Temperature Management Trial

**Conclusions:** Targeted temperature management at 33°C was associated with hemodynamic alterations with decreased heart rate, elevated levels of lactate, and need for increased vasopressor support compared with targeted temperature management at 36°C. Low mean arterial pressure and need for high doses of vasopressors were associated with increased mortality independent of allocated targeted temperature management. (*Crit Care*



N=950

Bro-Jeppesen et al.  
CCM 2014


Shock

Martin Annborn  
John Bro-Jeppesen  
Niklas Nielsen  
Susann Ullén  
Jesper Kjaergaard  
Christian Hassager  
Michael Wanscher  
Jan Hovdenes  
Tommaso Pellis  
Paolo Pelosi  
Matt P. Wise  
Tobias Cronberg  
David Erlinge  
Hans Friberg  
The TTM-trial investigators

# The association of targeted temperature management at 33 and 36 °C with outcome in patients with moderate shock on admission after out-of-hospital cardiac arrest: a post hoc analysis of the Target Temperature Management trial



ICM 2014



Mortality D180;  
 $p=0.17$

Mortality ICU;  $p=0.06$

After adjustment:  
 $p=0.03$

## TTM in PCAS on admission (n=139)



**Kilgannon et al. Early arterial hypotension is common in PCAS and associated with increased mortality. Resuscitation 2008**




Figure 2 Kaplan-Meier survival curves (truncated at 28 days)



IH mortality ↑ if exposures (n=66) vs not exposed (n=36). **More re-CA. Independantly associated with IH death** if early exposure

- Marie E. Beylin
- Sarah M. Perman
- Benjamin S. Abella
- Marion Leary
- Frances S. Shofer
- Anne V. Grossestreuer
- David F. Gaieski

**ICM 2013**

**Higher mean arterial pressure with or without vasoactive agents is associated with increased survival and better neurological outcomes in comatose survivors of cardiac arrest**

**(n=168)**





## ***Hemodynamic Optimization***

- In adult patients with ROSC after (OH / IH) CA, does **early hemodynamic optimization**, as opposed to standard care, improve outcome (survival)?
- **Post-CA myocardial dysfunction causes hemodynamic instability.**

## ***Treatment Recommendation***

- Despite limited clinical data, the known pathophysiology of post-CA syndrome provides a rationale for titrating hemodynamics to optimize organ perfusion.
- **Perform early echocardiography, fluid and inotropic support guided by clinical and biological parameters, target pressure for diuresis = 1 ml/kg/h and normal lactate (care if hypertension)**






## ***Knowledge Gaps ADAPT TTM ?***

- Clinical research is needed to define the optimal targets for hemodynamic optimization and the best strategies to achieve these targets (fluids, vasopressors, inotropes, circulatory support, etc).

# Bradycardia During Targeted Temperature Management: An Early Marker of Lower Mortality and Favorable Neurologic Outcome in Comatose Out-of-Hospital Cardiac Arrest Patients\*



Thomsen et al. *CCM*. 2016






Adjusted OR (CI 95%): 0.38 (0.21-0.68),  $p < 0.01$

n=430

# Possible ttt of PCAS patients (CS complicating AMI...)

## Algorithm proposed for the detection and management of postresuscitation myocardial dysfunction (PRMD)

Bougouin W, Cariou A. Curr Opin Crit Care 2013



De Chambrun et al ICM 16, Bougouin et al Resu 16

# Global hypothermia for neuroprotection after cardiac arrest

ORIGINAL ARTICLE

*Acute Cardiac Care*. 2006; 8: 25–30

Practical protocol for treatment of patients

FRITZ STERZ, WILHELM BEHRINGER & MICHAEL HOLZER

## WHO TO CONTROL TEMPERATURE?

All patients after CA

not obeying to verbal command after ROSC

## WHO NOT TO TREAT WITH 33-TTM (TH)?

TBI / intracranial hemorrhage,  
uncontrolled hemorrhagic shock,  
major uncontrolled bleeding (DIC?)


Initial temperature < 30°C, terminal disease, futility (?)

## WHEN TO ADAPT TTM?

Uncontrolled sepsis?

Uncontrolled shock ??? (but not bradycardia!)

Infants? pregnancy?



# CA etiology





2015




European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015  
Section 5 of the European Resuscitation Council Guidelines for Resuscitation 2015<sup>☆</sup>

Jerry P. Nolan<sup>a,b,\*</sup>, Jasmeet Soar<sup>c</sup>, Alain Cariou<sup>d</sup>, Tobias Cronberg<sup>e</sup>,  
Véronique R.M. Moulaert<sup>f</sup>, Charles D. Deakin<sup>g</sup>, Bernd W. Bottiger<sup>h</sup>, Hans Friberg<sup>i</sup>,  
Kjetil Sunde<sup>j</sup>, Claudio Sandroni<sup>k</sup>

## Summary of changes since 2010 guidelines




Diagnosis



# OPTIMIZING TTM/TH PROTOCOL

## TEMPERATURE MONITORING

Studies documenting improved outcome with therapeutic hypothermia after cardiac arrest used continuous temperature monitoring (LOE 1<sup>468</sup>; LOE






**Avoid overcooling and overheating!**  
**2/3 patients = overcooling**  
**(Merchant CCM 2006)**







Knapick. Resu 2011



Moran. CCM 2007




Zeiner Resu 2010

**ECMO  $\cong$  jugular bulb > esophagus  $\cong$  nasophar. > bladder  $\cong$  rectal**

Akata et al.  
J Thorac  
Cardiovasc  
Surg. 2007

Nussmeier.  
Anesth Analg  
2006



ECMO >

Jugular bulb (>) pulmonary artery

Naso-pharyngeal >

Bladder; Rectal >>> Tympanic

Cutaneous (unreliable)

Reliability  
measure ↓

Niven et al.  
A review.  
Ann Med Int 2015

# TTM IN ICU (EXCEPT NEONATES)

**French TTM recommendations 2016**  
Société de Réanimation de Langue Française  
Société Française d'Anesthésie et de Réanimation

**In collaboration with 5 French Medical Societies: Intensive care, Anesthesiology Resuscitation Council, Emergency Medicine, Neuro Intensive care, Neurovascular, Pediatric Society**

**Clinical fields: CA, TBI, stroke, status epilepticus, shock**

Recommendations are ranked by evidence (grade) and level of consensus reached among the experts (strong to weak)

## **Practical implementation and monitoring of TTM** **(question 6)**

**R 6.3. In patients treated by TTM, core body temperature measurement should probably be preferentially used**

**(Grade 2+) Strong agreement**

# OPTIMIZING TTM/TH PROTOCOL

## SIDE EFFECTS / MONITORING

ACSOS


# Hypothermia for neuroprotection in adults after cardiopulmonary resuscitation (Review)



CD 2010-2016

Arrich J, Holzer M, Herkner H, Müllner M

**No significant difference in reported adverse events between TH and control**



Safety profile and outcome of mild therapeutic hypothermia in patients following cardiac arrest: systematic review and meta-analysis

Rapport  
risque/bénéfice?

Guoguang Xiao,<sup>1</sup> Qin Guo,<sup>1</sup> Min Shu,<sup>1</sup> Xiaoping Xie,<sup>2</sup> Jianjun Deng,<sup>1</sup> Yu Zhu,<sup>1</sup> Chaomin Wan<sup>1,3</sup>

EMJ 2012 (*n=63 studies*)

**Most of adverse events potentially associated with TH (sepsis, bleeding...) were NS between HT and NT (except hypok<sup>+</sup>; pneumonia:  $p=0.06$ ; arrhythmia:  $p=0.05$ )**

Nielsen Niklas  
NEJM 2013

ORIGINAL ARTICLE

# Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest

Time from cardiac arrest to ROSC


Less than or equal to 25 min	79/243	86/241	0.92 [0.68, 1.24]
More than 25 min	156/230	138/224	1.20 [0.96, 1.50]

Shock at admission

Not present	183/402	180/398	1.03 [0.83, 1.28]
Present	52/70	44/67	1.35 [0.90, 2.03]

Site category

Two largest sites	50/110	40/108	1.33 [0.87, 2.03]
Sites except two largest	185/363	185/358	1.02 [0.83, 1.25]



	33°C	36°C	Total
	473	466	939
<b>Mechanical ventilation**</b>			
Days receiving mechanical ventilation/days in ICU median [IQR]	0.83 [0.67-1.00]	0.76 [0.60-1.00]	0.80 [0.60-1.00]
<b>Sedation</b>			
Days with sedation affecting neurological evaluation median [IQR]	2 [2-3]	2 [1-3]	2 [1-3]

(P=0.006)

**More hypoK+ if 33° C**  
**Trend for pneumonia**

# Main side-effects of TTM 30-36°C



## Risks



shivering, rhabdomyolysis, vasoconstriction

cardiovascular → ischemia,  $C_I \downarrow$ , brady-arrhythmias

respiratory →  $pCO_2 \downarrow$ ,  $pO_2 \downarrow$ ,  $pH \uparrow$ , congestion

coagulation → coagulopathy, hemorrhage, platelets, WBC (neutro)  $\downarrow$

infectious → sepsis, pneumonia, immunosuppression

renal: hyperdiuresis → hypovolemia

electrolytes →  $\downarrow K, Ph, Mg, Ca$

metabolic... → Hyperglycemia; ileus;  $\uparrow$  cortisol, epi+nor, ASAT, amylase; acidosis (lactate, fatty acid, ketone)



pharmacokinetic

# Adverse events and their relation to mortality in out-of-hospital cardiac arrest patients treated with therapeutic hypothermia\*

Niklas Nielsen, MD, PhD; Kjetil Sunde, MD, PhD; Jan Hovdenes, MD, PhD; Richard R. Riker, MD; Sten Rubertsson, MD, PhD; Pascal Stammet, MD; Fredrik Nilsson, PhD; Hans Friberg, MD, PhD; the Hypothermia Network

Crit Care Med 2011 Vol. 39, No. 1

(n=765 patients with full AE data collection, 22 centers)



**Adverse events were common after OHCA.**

**Sustained hyperglycemia & seizures treated with anticonvulsivants were associated with ↑ mortality (multivariate). Bleeding and infection were more common after invasive procedures, but not associated with increased mortality.**




# Infectious complications in out-of-hospital cardiac arrest patients in the therapeutic hypothermia era\*

CCM 2011



Nicolas Mongardon, MD; Sébastien Perbet, MD; Virginie Lemiale, MD; Florence Dumas, MD; Hélène Poupet, MD; Julien Charpentier, MD; Frédéric Péne, MD; Jean-Daniel Chiche, MD; Jean-Paul Mira, MD; Alain Cariou, MD

281/421 patients (67%) developed 373 infections:



New meta-analysis - review: Kavakas et al, J of Infection, 2015

# Early-Onset Pneumonia after Cardiac Arrest

## Characteristics, Risk Factors and Influence on Prognosis

Sébastien Perbet<sup>1,2</sup>, Nicolas Mongardon<sup>1,5</sup>, Florence Dumas<sup>3,9</sup>, Cédric Bruel<sup>2,8</sup>, Virginie Lemiale<sup>1</sup>,  
Bruno Mourvillier<sup>2</sup>, Pierre Carli<sup>4,5</sup>, Olivier Varenne<sup>5,6</sup>, Jean-Paul Mira<sup>1,5,7</sup>, Michel Wolff<sup>2,8</sup>,  
and Alain Cariou<sup>1,5,9</sup>

Am J Respir Crit Care Med Vol 184. pp 1048–1054, 2011



n=641 (TH: 500 pts, 78%)

EOP (<D3): 419 (65%)

**TH as an independant risk factor for EOP: OR 1.9**

**↑ MV, ICU stay duration but not VAP**

	Odds Ratio	Std. Err.	z	[95% Conf.Interval]	p value
Hypothermia	1.90	0.38	3.20	1.28-2.80	0.001
Male gender	1.15	0.21	0.75	0.80-1.65	0.45
Age (per quartile increase)	0.94	0.08	-0.77	0.79-1.11	0.44
Bystander	1.20	0.35	0.64	0.68-2.11	0.52
Shockable rhythm	1.20	0.22	1.02	0.85-1.71	0.31
Noflow<5 minutes	1.10	0.20	0.56	0.78-1.56	0.58
Lowflow<15 minutes	1.08	0.21	0.39	0.74-1.57	0.70
Epinephrine< 3mg	0.80	0.16	-1.16	0.54-1.17	0.25
Post-resuscitation Shock	1.11	0.20	0.56	0.78-1.56	0.58
SAPS II (per quartile increase)	1.06	0.09	0.63	0.89-1.26	0.53

**WE CAN USE ANTIOTIOTICS ! OR PROPHYLAXIS ?**

# **TTM IN ICU (EXCEPT NEONATES)**

## **French TTM recommendations 2016** **Société de Réanimation de Langue Française** **Société Française d'Anesthésie et de Réanimation**

**In collaboration with 5 French Medical Societies: Intensive care, Anesthesiology Resuscitation Council, Emergency Medicine, Neuro Intensive care, Neurovascular, Pediatric Society**

**Clinical fields: CA, TBI, stroke, status epilepticus, shock**

Recommendations are ranked by evidence (grade) and level of consensus reached among the experts (strong to weak)

## **Practical implementation and monitoring of TTM** **(question 6)**

**R6.4 – In patients treated by TTM, the occurrence of several complications should be monitored: sepsis, pneumonia, arrhythmia, hypokalemia**

**(Grade 2+) Strong agreement**



**Alain Cariou, JF Payen et al. AIC 2017**

# A Thromboelastometric Evaluation of the Effects of Hypothermia on the Coagulation System


Malin Rundgren, MD\*

(Anesth Analg 2008;107:1465-8)

Martin Engström, MD, PhD†



**Thrombocytopenia:**  
impaired coagulation  
cascade and platelet,  
**Coagulation disorders:**  
increase in bleeding  
time, APTT and PTT



## ***Blood Glucose Control : Treatment Recommendation***

- Strategies to treat hyperglycemia > 180 mg/dL (10 mmol/L) should be considered in adult patients with sustained ROSC after CA.
- Hypoglycemia should be avoided.

## ***Knowledge Gaps***



- Adequately powered intervention trials of moderate ranges of glucose control in patients who survive cardiac arrest are required.

### *Glucose control*


There is a strong association between high blood glucose after resuscitation from cardiac arrest and poor neurological outcome.<sup>261,439,440</sup> Based on the available data, following ROSC maintain the blood glucose at  $\leq 10 \text{ mmol l}^{-1}$  ( $180 \text{ mg dl}^{-1}$ ) and avoid hypoglycaemia.<sup>441</sup> Do not implement strict glucose control in adult patients with ROSC after cardiac arrest because it increases the risk of hypoglycaemia.

Tuomas Oksanen  
Markus B. Skrifvars  
Tero Varpula  
Anne Kuitunen  
Ville Pettilä  
Jouni Nurmi  
Maaret Castrén

## Strict versus moderate glucose control after resuscitation from ventricular fibrillation



P=0,846



Resuscitation 2008

# Strict normoglycaemic blood glucose levels in the therapeutic management of patients within 12 h after cardiac arrest might not be necessary

Heidrun Losert<sup>a</sup>, Fritz Sterz<sup>a,\*</sup>, Risto O. Roine<sup>b</sup>, Michael Holzer<sup>a</sup>, Patrick Martens<sup>c</sup>, Erga Cerchiari<sup>d</sup>, Marjaana Tiainen<sup>b</sup>, Marcus Müllner<sup>a</sup>, Anton N. Laggner<sup>a</sup>, Harald Herkner<sup>a</sup>, Martin G. Bischof<sup>e</sup>

- Retrospective analysis of data obtained from the European RCT about the effect of mild hypothermia after cardiac arrest
  - Adjustment (in multivariate analysis) for sex, "no-flow" and "low-flow" ROSC, epinephrine dose administered during CPR, reoccurrence of CA after CPR, hypothermia, history of CHD or MI
- Resuscitation (2008) 76, 214–220



## Odds ratio of good neurological recovery after cardiac arrest

	<b>Group 1 (67-115)</b>	<b>Group 2 (116-143)</b>	<b>Group 3 (144-193)</b>	<b>Group 4 (194-464)</b>
Med [IQR25-75]	100 [94-108]	130 [123-135]	159 [150-175]	255 [207-292]
OR [IC95%]	4.55 (1.28-16.12)	13.02 (3.29-49.9)	1.37 (0.38-5.64)	1 (ref)

# Blood glucose level and outcome after cardiac arrest: insights from a large registry in the hypothermia era

ICM 2014

Daviaud F, Dumas F, Demars N, Geri G, Bouglé A, Morichau-Beauchant T, Nguyen YL, Bougouin W, Pène F, Charpentier J, Cariou A



multivariate analysis, an increased median BG level over the first 48 h was found to be an independent predictor of poor issue [OR = 0.43; 95 % CI (0.24–0.78),  $p = 0.006$ ].




## O<sub>2</sub> / CO<sub>2</sub>: NEW GUIDELINES

cardiac arrest, as soon as arterial blood oxygen saturation can be monitored reliably (by blood gas analysis and/or pulse oximetry), titrate the inspired oxygen concentration to maintain the arterial blood oxygen saturation in the range of 94–98%. Avoid hypoxaemia, which is also harmful – ensure reliable measurement of arterial oxygen saturation before reducing the inspired oxygen concentration.

it is reasonable to adjust ventilation to achieve normocarbia and to monitor this using the end-tidal CO<sub>2</sub> and arterial blood gas values.


# Association Between Arterial Hyperoxia Following Resuscitation From Cardiac Arrest and In-Hospital Mortality

Kilgannon JH et al. The Emergency Medicine Shock Research Network. JAMA. 2010;303:2165-71



## Independent predictors of in-hospital mortality

Variable	OR (95% CI)	P Value
Age decile	1.1 (1.1-1.2)	<.001
Emergency department origin	1.5 (1.3-1.7)	<.001
Nonindependent functional status at admission	1.3 (1.1-1.4)	<.001
Chronic renal failure	1.6 (1.3-1.9)	<.001
Active chemotherapy	2.8 (1.8-4.6)	<.001
High heart rate in ICU <sup>b</sup>	1.9 (1.7-2.1)	<.001
Hypotension at ICU arrival <sup>c</sup>	2.1 (1.9-2.3)	<.001
Hypoxia exposure	1.3 (1.1-1.5)	.009
Hyperoxia exposure	1.8 (1.5-2.2)	<.001



# OXYGEN: WHAT'S NEW AFTER ROSC?



American Journal of Emergency Medicine

2014



journal homepage: [www.elsevier.com/locate/ajem](http://www.elsevier.com/locate/ajem)

The American Journal of  
Emergency Medicine

Association between mean arterial blood gas tension and outcome in cardiac arrest patients treated with therapeutic hypothermia<sup>☆</sup>

Byung Kook Lee, MD, PhD<sup>a</sup>, Kyung Woon Jeung, MD, PhD<sup>a,\*</sup>, Hyoung Youn Lee, MD<sup>b</sup>, Seung Joon Lee, MD<sup>c</sup>, Yong Hun Jung, MD<sup>a</sup>, Wang Ki Lee, MD<sup>a</sup>, Tag Heo, MD, PhD<sup>a</sup>, Yong Il Min, MD, PhD<sup>a</sup>

213 patients > 16 yo with CA (OHCA 83%, 2008-12). TH 100%. **Mean PaO<sub>2</sub> (8 ABG)** from ROSC to rewarming. **Hyperoxia <3%**



**Multivariate: mean PaO<sub>2</sub> not associated with IH-death**

**Multivariate: PaO<sub>2</sub> (1<sup>st</sup> 2<sup>nd</sup> 3<sup>rd</sup> quartiles) associated with poor neurologic outcome**

**V-shaped relationship between PaO<sub>2</sub> and poor CPC (best ~ 130mmHg)**


# OXYGEN: WHAT'S NEW AFTER ROSC?

## The Effect of Hyperoxia on Survival Following Adult Cardiac Arrest: A

### Systematic Review and Meta-analysis of Observational Studies

Author: Chih-Hung Wang Wei-Tien Chang Chien-Hua Huang  
Min-Shan Tsai Ping-Hsun Yu An-Yi Wang Nai-Chuan Chen  
Wen-Jone Chen

2014



Studies comparing oxygen vs normoxia alone excluded  
10 studies pooled in meta-analysis (out of 16 assessed for eligibility)

Hyperoxia: PaO<sub>2</sub> > 300 mmHg

Results were inconsistent in subgroups, with significant heterogeneity and limited studies

## In hospital mortality


OR 1.40 (1.02-1.93), R<sup>2</sup> 0.69

### First author (Year)

Kilgannon (2010)  
Bellomo (2011)  
Janz (2012)  
Ihle (2013)  
Nelskyla (2013)  
Lee (2010)  
Gaieski (2012)  
Pullalarevu (2012)

### Random-Effects Model

Test for Heterogeneity: p-value = 0.004  
I<sup>2</sup> (% of total variability due to heterogeneity): 69.27%




# OXYGEN: WHAT'S NEW AFTER ROSC?

## The Effect of Hyperoxia on Survival Following Adult Cardiac Arrest: A

### Systematic Review and Meta-analysis of Observational Studies

Author: Chih-Hung Wang Wei-Tien Chang Chien-Hua Huang  
Min-Shan Tsai Ping-Hsun Yu An-Yi Wang Nai-Chuan Chen  
Wen-Jone Chen

2014



Studies comparing oxygen vs normoxia alone excluded  
10 studies pooled in meta-analysis (out of 16 assessed for eligibility)

Hyperoxia:  $PaO_2 > 300$  mmHg

Results were inconsistent in subgroups, with significant heterogeneity and limited studies

**Poor neurologic outcome at hospital discharge**

**OR 1.62 (0.87-3.02),  $R^2$  0.55**



#### First author (Year)


Janz (2012)

Roberts (2013)

#### Fixed-Effects Model



Test for Heterogeneity: p-value = 0.1334

$I^2$  (% of total variability due to heterogeneity): 55.61%



# CO<sub>2</sub>: WHAT'S NEW ?

## CBF and PaCO<sub>2</sub> in brain



Jones TH, Morawetz RB, Crowell RM, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 1981; 54:773-782

**Decreasing PaCO<sub>2</sub> of 1 mmHg decreasing CBF of 3%**

**ESTIMATION OF CO<sub>2</sub>-INDUCED CHANGES IN CEREBRAL BLOOD FLOW BY TRANSCRANIAL DOPPLER SONOGRAPHY: A VALIDATION STUDY**

Weyland J Cardiothorac Vasc Anesth 1994

# Association Between Postresuscitation Partial Pressure of Arterial Carbon Dioxide and Neurological Outcome in Patients With Post-Cardiac Arrest Syndrome

Circulation  
JOURNAL OF THE AMERICAN HEART ASSOCIATION

Brian W. Roberts, MD; J. Hope Kilgannon, MD; Michael E. Chansky, MD; Neil Mittal, MD; Jonathan Wooden, MD; Stephen Trzeciak, MD, MPH

2013



Retrospective and single center; 193 nontraumatic comatose OHCA  $\geq 18$  yo + all ABGs  $\leq 24$ h after ROSC

No exposure 31%  
PaCO<sub>2</sub>  $\geq 50$  mmHg

Hypocapnia only 27%  
PaCO<sub>2</sub>  $\leq 30$  mmHg

Hypercapnia only 33%  
PaCO<sub>2</sub>  $\geq 50$  mmHg

Both 9%  
PaCO<sub>2</sub>  $\leq 30$  mmHg




Hypo- & hyper-capnia are common & independently associated with poor neurologic outcome

# Association between mean arterial blood gas tension and outcome in cardiac arrest patients treated with therapeutic hypothermia<sup>☆</sup>

Byung Kook Lee, MD, PhD<sup>a</sup>, Kyung Woon Jeung, MD, PhD<sup>a,\*</sup>, Hyoung Youn Lee, MD<sup>b</sup>, Seung Joon Lee, MD<sup>c</sup>, Yong Hun Jung, MD<sup>a</sup>, Wang Ki Lee, MD<sup>a</sup>, Tag Heo, MD, PhD<sup>a</sup>, Yong Il Min, MD, PhD<sup>a</sup>

**213 CA patients with TH > 16 yo. Mean PaCO<sub>2</sub> (8 ABG)**



**Multivariate: hypocarbia but not hypercarbia independently associated with increased risk of IH-death (OR 2.52, CI95% 1.18-5.37, P=0.016);**  
**U-shaped relationship between PaCO<sub>2</sub> and IH mortality (best ~ 35-45mmHg)**  
**Hypocarbia & hypercarbia not associated with increased poor neurologic outcome**




# Arterial Blood Gas Tensions After Resuscitation From Out-of-Hospital Cardiac Arrest: Associations With Long-Term Neurologic Outcome\*

CCM 2014

Jukka Vaahersalo, MD<sup>1</sup>; Stepani Bendel, MD, PhD<sup>2</sup>; Matti Reinikainen, MD, PhD<sup>3</sup>; Jouni Kurola, MD, PhD<sup>4</sup>; Marjaana Tiainen, MD, PhD<sup>5</sup>; Rahul Raj, BM<sup>1</sup>; Ville Pettilä, MD, PhD<sup>1</sup>; Tero Varpula, MD, PhD<sup>1</sup>; Markus B. Skrifvars, MD, PhD, FCICM<sup>1</sup>; for the FINNRESUSCI Study Group

**409 OHCA pts with  $\geq 1$  ABG. TH 71%**  
**8 PaCO<sub>2</sub> measurements/patient  $\leq$  24h.**

Characteristic		All Patients (n = 409)	Patients With Good Outcome (n = 168)	Patients With Poor Outcome (n = 241)	p
Proportion of time (%) spent in carbon dioxide range					
Low	< 30 mm Hg	3% (0–59%)	0% (0–82%)	1.001 (0.990–1.012)	0.88
Middle	30–37.5 mm Hg	54% (0–91%)	51% (0–98%)	0.993 (0.985–1.002)	0.12
Intermediate	37.5–45 mm Hg	21% (0–85%)	15% (0–92%)	1.001 (0.992–1.0010)	0.82
High	> 45 mm Hg	0% (0–61%)	0% (0–59%)	1.015 (1.002–1.029)	0.024




**Hypercapnia was associated with good 1 year outcome**  
**The mean 24h PaCO<sub>2</sub> was independent predictor of good outcome**  
**Time spent in PaCO<sub>2</sub> > 45 mmHg was independent associated with good outcome**

European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015  
Section 5 of the European Resuscitation Council Guidelines for Resuscitation 2015<sup>☆</sup>



Jerry P. Nolan<sup>a,b,\*</sup>, Jasmeet Soar<sup>c</sup>, Alain Cariou<sup>d</sup>, Tobias Cronberg<sup>e</sup>,  
Véronique R.M. Moulaert<sup>f</sup>, Charles D. Deakin<sup>g</sup>, Bernd W. Bottiger<sup>h</sup>, Hans Friberg<sup>i</sup>,  
Kjetil Sunde<sup>j</sup>, Claudio Sandroni<sup>k</sup>

Summary of changes since 2010 guidelines



# Practical protocol for treatment of patients

**Sedatives**

**Analgesics**

**Neuromuscular blockers**

**Normoxia in controlled MV ( $\text{PaO}_2$ : 60-200mmHg)**

**Normocapnia (4.9-5.5 kPa = 37-42 mmHg)**

**Hemodynamic optimization (and cerebral perfusion pressure), euvolemia**  
( $\text{SAP} > 90$  mmHg,  $\text{MAP} \geq 70$  mmHg, diuresis  $\geq 1\text{ml/kg/h}$ )

**Normo-natremia, -kaliemia, -magnesemia, -phosphoremia, -calcemia**

**Normoglycemia (insuline protocol to treat hyperglycemia  $> 1.80$  g/L ( $>10$  mmol/L), hypoglycemia avoided, target within 12H after CA : 1.16-1.43 g/L)**

**Semi-recumbent position in bed (30-45° )**

**Prophylactic treatments: heparin, anti-arrhythmics**



*Sterz F, Behringer W, Holzer M. 2006. Global hypothermia for neuroprotection. Acute Cardiac Care.*  
*Sunde K. Resuscitation. 2007. Implementation of a standardised protocol for post resuscitation care.*  
*Deye N. Textbook "Acute heart failure syndromes" . 2007. Acute cardiac failure & neuroprotection.*  
*Kupchnick NL. CCM. 2009. Suppl. Implementation of a TH protocol.*  
*Seder DB, Van der Kloot TE. CCM. 2009. Suppl. Methods of cooling. Practical aspects.*

**Review of protocol utility during TH (neg. /40) : Freund, Cardiol J, 2017**


# Sedation Confounds Outcome Prediction in Cardiac Arrest Survivors Treated with Hypothermia

Neurocrit Care 2011

Edgar A. Samaniego, Michael Mlynash, Anna Finley Caulfield, Irina Eyingorn, and Christine A. C. Wijman

Stanford University School of Medicine, Stanford University Medical Center, 780 Welch Road, Suite 205, Palo Alto, CA 94304, USA

n=85 (53 poor outcome = 65%; 53 hypothermia = 62% ; 62 sedative H60 = 73%)




\* Neuromuscular blockade was utilized to treat shivering during hypothermia.  
SSEP = somatosensory-evoked potentials; NSE = neuron specific enolase.

**Patients treated with TH are more likely to receive sedation.  
Sedatives are an important prognostication confounder.  
Midazolam can prolong consciousness recovery time & delay extubation  
Sedatives in both TH and non-TH patients may confound clinical exam.**

Fugate Wijdicks, et al Annals Neurology 2010

# Sedation (with their pharmacokinetic) and TH (TTM) will affect recovery ... & prognosis




A comparison of therapeutic hypothermia and strict therapeutic normothermia after cardiac arrest

Casamento, et al Resuscitation 2016

In 2 ICUs, a before-after study (2 X 69), no differences in feasibility (proportion of within range temperatures); doses of midazolam, fentanyl, NMB, fever in the first 96h and shivering were lower in 36-TTM compared with TH.

# Influence of the temperature on the moment of awakening in patients treated with therapeutic hypothermia after cardiac arrest<sup>☆</sup>

Ponz et al et al Resuscitation 2017



Delay of 5 days if 33° C ?


*Results:* We included 163 CA survivors (84.7% male, 60.2 years) who regained consciousness after TTM: target temperature was either 32 °C (36.2%), 33 °C (56.4%) or 34 °C (6.7%). Mean time of awakening was 3.8 days. Thirty-four patients (20.9%) regained neurological responsiveness after 5 days after CA. All of them had been cooled to either 32 °C (18 patients) or 33 °C (16), and no patient cooled to 34 °C awakened after day 5. A lower target temperature was associated with a later awakening ( $p < 0.001$ ). The time to advanced cardiopulmonary resuscitation (CPR) was shorter among the early awakers ( $p = 0.04$ ), but we found no other predictors of an earlier awakening.



# Changes in cardiac arrest patients' temperature management after the 2013 "TTM" trial: results from an international survey

Nicolas Deye<sup>1\*</sup>, François Vincent<sup>2</sup>, Philippe Michel<sup>3</sup>, Stephan Ehrmann<sup>4</sup>, Daniel da Silva<sup>5</sup>, Michael Piagnerelli<sup>6</sup>, Antoine Kimmoun<sup>7</sup>, Olfa Hamzaoui<sup>8</sup>, Jean-Claude Lacherade<sup>9</sup>, Bernard de Jonghe<sup>10</sup>, Florence Brouard<sup>3</sup>, Corinne Audoin<sup>11</sup>, Xavier Monnet<sup>12</sup>, Pierre-François Laterre<sup>13</sup> and For the SRLF Trial Group

During TTM, do you use sedatives? (n=423)



	Response	N
<b>Always</b>	<b>85%</b>	<b>358</b>
Frequently	11%	47
Sometimes	4%	16
Never	0,2%	1
Unknown	0,2%	1


**Studies with hepatically eliminated (active) drugs suggest  $\approx 11\%$  reduction in clearance per  $^{\circ}\text{C}$  change.** Hepatic metabolism (CYP450) is decreased if TTM for hepatically metabolized drugs ( $\approx$  NMB, sedatives, analgesics, anticonvulsivants...)



# Changes in cardiac arrest patients' temperature management after the 2013 "TTM" trial: results from an international survey

Nicolas Deye<sup>1\*</sup>, François Vincent<sup>2</sup>, Philippe Michel<sup>3</sup>, Stephan Ehrmann<sup>4</sup>, Daniel da Silva<sup>5</sup>, Michael Piagnerelli<sup>6</sup>, Antoine Kimmoun<sup>7</sup>, Olfa Hamzaoui<sup>8</sup>, Jean-Claude Lacherade<sup>9</sup>, Bernard de Jonghe<sup>10</sup>, Florence Brouard<sup>3</sup>, Corinne Audoin<sup>11</sup>, Xavier Monnet<sup>12</sup>, Pierre-François Laterre<sup>13</sup> and For the SRLF Trial Group

During TTM, do you use analgesics?  
(n=423)



	Response	N
<b>Always</b>	<b>79%</b>	<b>332</b>
<b>Frequently</b>	<b>14%</b>	<b>58</b>
Sometimes	6%	25
Never	1%	6
Unknown	0,5%	2


**30% reductions in dosage per 5° C for remifentanil**



Thor W. Bjelland  
Ola Dale  
Kjell Kaisen  
Bjørn O. Haugen  
Stian Lydersen  
Kristian Strand  
Pål Klepstad

# Propofol and remifentanil versus midazolam and fentanyl for sedation during therapeutic hypothermia after cardiac arrest: a randomised trial

Bjelland ICM 2012




Midazolam can prolong consciousness recovery time & delay extubation



# Changes in cardiac arrest patients' temperature management after the 2013 "TTM" trial: results from an international survey

Nicolas Deye<sup>1\*</sup>, François Vincent<sup>2</sup>, Philippe Michel<sup>3</sup>, Stephan Ehrmann<sup>4</sup>, Daniel da Silva<sup>5</sup>, Michael Piagnerelli<sup>6</sup>, Antoine Kimmoun<sup>7</sup>, Olfa Hamzaoui<sup>8</sup>, Jean-Claude Lacherade<sup>9</sup>, Bernard de Jonghe<sup>10</sup>, Florence Brouard<sup>3</sup>, Corinne Audoin<sup>11</sup>, Xavier Monnet<sup>12</sup>, Pierre-François Laterre<sup>13</sup> and For the SRLF Trial Group

During TTM, do you use paralyzers NMB? (n=423)



	Response	N
<b>Always</b>	<b>48%</b>	<b>201</b>
<b>Frequently</b>	<b>31%</b>	<b>129</b>
Sometimes	19%	81
Never	3%	11
Unknown	0,2%	1

**Shivering monitoring (Bedside Shivering Assessment scale... TOF)**


Badjatia, Mayer. CCM 2009

**Shivering treatment (Mg, buspirone, meperidine, opioids, dexmetomidine, propofol... paralyzers)**

# Impairment of autonomic cold defenses by anesthetics (hypothalamic set point)

Matsukawa T et al. *Anesthesiology* 1995

- Volatile anesthetics ?!
- Propofol
- Opioids
  - Meperidine
- Non opioids
  - Nefopam
  - Clonidine
  - Dexmedetomidine
  - Buspirone
- Drug combinations (without interactions: CYP450) ?!



Prefer IV administration if possible (ileus during TTM)

Use short-acting drugs with short half-life time

Adapt doses and use strict monitoring


European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015  
 Section 5 of the European Resuscitation Council Guidelines for Resuscitation 2015<sup>☆</sup>



To 2015

Jerry P. Nolan<sup>a,b,\*</sup>, Jasmeet Soar<sup>c</sup>, Alain Cariou<sup>d</sup>, Tobias Cronberg<sup>e</sup>,  
 Véronique R.M. Moulaert<sup>f</sup>, Charles D. Deakin<sup>g</sup>, Bernd W. Bottiger<sup>h</sup>, Hans Friberg<sup>i</sup>,  
 Kjetil Sunde<sup>j</sup>, Claudio Sandroni<sup>k</sup>


**Prognostication with a multimodal strategy ++  
 Allow sufficient time for neurological recovery & for sedatives' clearance**




Clinical data ++  
 Biomarker  
 EEG, SEP  
 Brain CT-scan  
 (MRI)  
 (Doppler)

# OPTIMIZING TTM/TH PROTOCOL

## WHICH METHOD? *Advanced vs basic*



Holzer NEJM 2010



## ILCOR Advisory Statement

### Therapeutic Hypothermia After Cardiac Arrest

An Advisory Statement by the Advanced Life Support Task Force of the  
International Liaison Committee on Resuscitation

External or internal cooling techniques can be  
used to initiate cooling within minutes to hours

2003

Rapid infusion of ice-cold IV fluid 30 mL/kg or ice packs are feasible, safe, and simple methods for initially lowering core temperature up to 1.5° C. When IV fluids are used to induce hypothermia, additional cooling strategies will be required to maintain hypothermia.

2010

2015


*How to control temperature?. As yet, there are no data indicating that any specific cooling technique increases survival when compared with any other cooling technique; however, internal devices enable more precise temperature control compared with external*

# Endovascular Versus External Targeted Temperature Management for Patients With Out-of-Hospital Cardiac Arrest

A Randomized, Controlled Study

Deye N et al (ICEREA).  
Circulation 2015

## Cumulative survival rate without major sequelae within 90 days



# TTM IN ICU (EXCEPT NEONATES)

**French TTM recommendations 2016**  
Société de Réanimation de Langue Française  
Société Française d'Anesthésie et de Réanimation

**In collaboration with 5 French Medical Societies: Intensive care, Anesthesiology Resuscitation Council, Emergency Medicine, Neuro Intensive care, Neurovascular, Pediatric Society**

**Clinical fields: CA, TBI, stroke, status epilepticus, shock**

Recommendations are ranked by evidence (grade) and level of consensus reached among the experts (strong to weak)

## **Practical implementation and monitoring of TTM** (question 6)

**R6.1 - In patients treated by TTM, advanced methods (i.e. with automated feedback) compared to basic methods should be used to optimize TTM**

**(Grade 1+) Strong agreement**



# OPTIMIZING TTM/TH PROTOCOL

## OPTIMIZED START AND DURATION

OPTIMAL DURATION = 24H

for TTM  $\leq 36^{\circ}$  C

+ Duration of normothermia  $\leq 37.5^{\circ}$  C = 72H



- If targeted temperature management is used, it is suggested that the duration is at least 24 h (as undertaken in the two largest previous RCTs<sup>376,450</sup>) (weak recommendation, very low-quality evidence).

Rebound hyperthermia is associated with worse neurological outcome.<sup>463,464</sup> Thus, rewarming should be achieved slowly: the optimal rate is not known, but the consensus is currently about 0.25–0.5 °C of rewarming per hour.<sup>465</sup>

# Targeted Temperature Management for 48 vs 24 Hours and Neurologic Outcome After Out-of-Hospital Cardiac Arrest A Randomized Clinical Trial

JAMA 2017

Hans Kirkegaard, MD, PhD, DMSci, DEAA, DLS; Eldar Søreide, MD, PhD, FERC; Inge de Haas, MD; Ville Pettilä, MD, PhD, EDIC; Fabio Silvio Taccone, MD, PhD; Urmet Arus, MD; Christian Storm, MD, PhD; Christian Hassager, MD, DMSc; Jørgen Feldbæk Nielsen, MD, DMSci; Christina Ankjær Sørensen, MD; Susanne Ilkjær, MD, PhD; Anni Nørgaard Jeppesen, MD; Anders Morten Grejs, MD, PhD; Christophe Henri Valdemar Duez, MD; Jakob Hjort, MPH; Alf Inge Larsen, MD, PhD, FESC; Valdo Toome, MD; Marjaana Tiainen, MD, PhD; Johanna Hästbacka, MD, PhD; Timo Laitio, MD, PhD; Markus B. Skrifvars, MD, PhD, EDIC, FCICM



No. at risk	0	50	100	150	200
48-h group	175	131	128	128	127
24-h group	177	125	117	120	117

N=176 vs 179

	No. (%) of Patients		Difference, % (95% CI)	RR (95% CI)	P Value
	48-Hour Group (n = 175)	24-Hour Group (n = 176)			
Primary outcome: CPC score of 1 or 2 at 6 mo	120 (69)	112 (64)	4.9 (-5 to 14.8)	1.08 (0.93 to 1.25)	.33
Secondary outcomes					
Mortality at 6 mo	48 (27)	60 (34)	-6.5 (-16.1 to 3.1)	0.81 (0.59 to 1.11)	.19
Any adverse event	169 (97)	161 (91)	5.6 (0.6 to 10.6)	1.06 (1.01 to 1.12)	.03